vorinostat has been researched along with Interstitial Cell Tumor in 1 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Maggisano, V | 1 |
| Puppin, C | 1 |
| Celano, M | 1 |
| D'Agostino, M | 1 |
| Sponziello, M | 1 |
| Micali, S | 1 |
| Navarra, M | 1 |
| Damante, G | 1 |
| Filetti, S | 1 |
| Russo, D | 1 |
1 other study available for vorinostat and Interstitial Cell Tumor
| Article | Year |
|---|---|
Cooperation of histone deacetylase inhibitors SAHA and valproic acid in promoting sodium/iodide symporter expression and function in rat Leydig testicular carcinoma cells.
Topics: Animals; Cell Line, Tumor; Cells, Cultured; Drug Evaluation, Preclinical; Drug Synergism; Gene Expre | 2014 |